Literature DB >> 21506683

Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection.

G M Chen1, N Hu, L Liu, S S Xie, P Wang, J Li, L Xie, G J Wang, X D Liu.   

Abstract

The aim of this study was to investigate effects of type 2 diabetes on the pharmacokinetics of verapamil after intravenous administration. Diabetes mellitus (DM) rats were induced by combination of high-fat diet (HFD) and streptozotocin. Plasma concentrations of verapamil in DM rats, rats fed with HFD, and control (CON) rats were measured after intravenous administration of 1 mg/kg verapamil and corresponding pharmacokinetic parameters were estimated. Area under the plasma concentration in DM rats was significantly smaller than that in CON rats. In vitro microsomal study showed that intrinsic clearance of verapamil in DM rats was significantly higher than those in CON rats. Compared to CON rats, higher intrinsic clearance was also observed in HFD rats. Western blot results demonstrated higher levels of CYP3A2 in DM and HFD rats, which was in line to activity of CYP3A. All the results gave a conclusion that diabetes may enhance metabolism of verapamil in rat, and the enhancement may partly result from induction of CYP3A.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21506683     DOI: 10.3109/00498254.2011.558933

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  8 in total

1.  Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes.

Authors:  Dan Xu; Feng Li; Mian Zhang; Ji Zhang; Can Liu; Meng-yue Hu; Ze-yu Zhong; Ling-ling Jia; Da-wei Wang; Jie Wu; Li Liu; Xiao-dong Liu
Journal:  Acta Pharmacol Sin       Date:  2014-08-25       Impact factor: 6.150

2.  Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure.

Authors:  Feng Li; Mian Zhang; Dan Xu; Can Liu; Ze-Yu Zhong; Ling-Ling Jia; Meng-Yue Hu; Yang Yang; Li Liu; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2014-06       Impact factor: 6.150

Review 3.  Strategies for preclinical pharmacokinetic investigation in streptozotocin-induced diabetes mellitus (DMIS) and alloxan-induced diabetes mellitus (DMIA) rat models: case studies and perspectives.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-03-06       Impact factor: 2.441

4.  Modulation of CYP3a expression and activity in mice models of type 1 and type 2 diabetes.

Authors:  Dany Patoine; Michaël Petit; Sylvie Pilote; Frédéric Picard; Benoit Drolet; Chantale Simard
Journal:  Pharmacol Res Perspect       Date:  2014-09-01

5.  Adiponectin protects against lung ischemia-reperfusion injury in rats with type 2 diabetes mellitus.

Authors:  Di Li; Lin-Lin Song; Juan Wang; Chao Meng; Xiao-Guang Cui
Journal:  Mol Med Rep       Date:  2018-03-14       Impact factor: 2.952

6.  Dexmedetomidine Alleviates Lung Oxidative Stress Injury Induced by Ischemia-Reperfusion in Diabetic Rats via the Nrf2-Sulfiredoxin1 Pathway.

Authors:  Xuan Wang; Bing Zhang; Guangqi Li; Han Zhao; Xiaojun Tian; Junmin Yu; Yanwei Yin; Chao Meng
Journal:  Biomed Res Int       Date:  2022-02-24       Impact factor: 3.411

Review 7.  Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity.

Authors:  Lucy Darakjian; Malavika Deodhar; Jacques Turgeon; Veronique Michaud
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

Review 8.  Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance.

Authors:  Yiting Yang; Xiaodong Liu
Journal:  Pharmaceutics       Date:  2020-04-11       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.